Cognitive decline is frequently seen in patients with chronic kidney disease (CKD). The causes of cognitive decline in these patients are likely to be multifactorial, including vascular disease, uraemic toxins, blood–brain barrier leakage, and metabolic and endocrine changes. Gut dysbiosis is common in patients with CKD and contributes to the increase in uraemic toxins. However, the gut microbiome modulates local and systemic levels of several metabolites such as short-chain fatty acids or derivatives of tryptophan metabolism, neurotransmitters, endocannabinoid-like mediators, bile acids, hormones such as glucagon-like peptide 1 (GLP1) or cholecystokinin (CCK). These factors can affect gut function, immunity, autonomic nervous system activity and various aspects of brain function. Key areas include blood–brain barrier integrity, nerve myelination and survival/proliferation, appetite, metabolism and thermoregulation, mood, anxiety and depression, stress and local inflammation. Alterations in the composition of the gut microbiota and the production of biologically active metabolites in patients with CKD are well documented and are favoured by low-fiber diets, elevated urea levels, sedentary lifestyles, slow stool transit times and polypharmacy. In turn, dysbiosis can modulate brain function and cognitive processes, as discussed in this review. Thus, the gut microbiome may contribute to alterations in cognition in patients with CKD and may be a target for therapeutic interventions using diet, prebiotics and probiotics.
The role of the intestinal microbiome in cognitive decline in patients with kidney disease / Wagner, C. A.; Frey-Wagner, I.; Ortiz, A.; Unwin, R.; Liabeuf, S.; Suzumoto, Y.; Iervolino, A.; Stasi, A.; Marzo, V. D.; Gesualdo, L.; Massy, Z. A.; Capasso, G.; Bachmann, M.; Andrade, A.; Arici, M.; Bailey, M.; Barbieri, M.; Bobot, M.; Bruchfeld, A.; Arune-Bumblyte, I.; Rastenyte, D.; Calcutta, A.; Capolongo, G.; Carriazo, S.; Ceccarelli, M.; Covic, A. C.; De, A.; Delgado, P.; Endlich, N.; Endres, M.; Esposito, F.; Farisco, M.; Faucher, Q.; Ferreira, A. C.; Figurek, A.; Fouque, D.; Franssen, C.; Fridolin, I.; Frische, S.; Garneata, L.; Giannakou, K.; Godefroy, O.; Golenia, A.; Goumenos, D.; Jimenez, E. G.; Hafez, G.; Hoorn, E.; Imenez Silva, P. H.; Izhar, R.; Kelly, D.; Kesler, S.; Klimkowicz-Mrowiec, A.; Knauss, S.; Kurganaite, J.; Levassort, H.; Malyszko, J.; Mani, L. -Y.; Martino, G.; Massy, Z.; Mayer, C.; Mucci, A.; Mutevelic-Turkovic, A.; Nielsen, R.; Nitsch, D.; Panagiotopoulos, V.; Karasavvidou, D.; Paolisso, G.; Pejuskovic, B.; Pepin, M.; Perna, A.; Perrottelli, A.; Pesic, V.; Pezzella, P.; Rroji, M.; Rychlik, I.; Sakkas, G.; Simeoni, M.; Soler Romeo, M. J.; Spasovski, G.; Starcevic, A.; Tedeschi, G.; Trevisani, F.; Vazelov, E.; Wagner, C. A.; Wagner, F.; Wanner, C.; Wiecek, A.; Xu, H.; Zacchia, M.; Zacharia, L.; Zecchino, I.; Zoccali, C.; Mattace-Raso, F.; Endlich, K. -H.; Perico, N.; Remuzzi, G.; Trepiccione, F.; Okusa, M.; Marzo, V. D.; Blankestijn, P.; Eckardt, K. -U.; Konig, M.; Gansevoort, R.; Askari, H.; Hansen, B.; Snaedal, S.; Cuiban, E.; Caporusso, E.; Re, V. L.; Roiser, J.; Rosenberg, K.; Bisecco, A.; Denby, L.; Kulkarni, O. P.; Sharma, K.; Debnath, S.; Jaafar, A.; Capasso, A.; Mulholland, M.; Workeneh, B.; Fraser, S.; Pastore, A.; De Donato, A.; Maciulaitis, R.; Farinha, A.. - In: NEPHROLOGY DIALYSIS TRANSPLANTATION. - ISSN 0931-0509. - 40:(2025), pp. 4-17. [10.1093/ndt/gfae253]
The role of the intestinal microbiome in cognitive decline in patients with kidney disease
Martino G.;Trevisani F.;Capasso A.;
2025-01-01
Abstract
Cognitive decline is frequently seen in patients with chronic kidney disease (CKD). The causes of cognitive decline in these patients are likely to be multifactorial, including vascular disease, uraemic toxins, blood–brain barrier leakage, and metabolic and endocrine changes. Gut dysbiosis is common in patients with CKD and contributes to the increase in uraemic toxins. However, the gut microbiome modulates local and systemic levels of several metabolites such as short-chain fatty acids or derivatives of tryptophan metabolism, neurotransmitters, endocannabinoid-like mediators, bile acids, hormones such as glucagon-like peptide 1 (GLP1) or cholecystokinin (CCK). These factors can affect gut function, immunity, autonomic nervous system activity and various aspects of brain function. Key areas include blood–brain barrier integrity, nerve myelination and survival/proliferation, appetite, metabolism and thermoregulation, mood, anxiety and depression, stress and local inflammation. Alterations in the composition of the gut microbiota and the production of biologically active metabolites in patients with CKD are well documented and are favoured by low-fiber diets, elevated urea levels, sedentary lifestyles, slow stool transit times and polypharmacy. In turn, dysbiosis can modulate brain function and cognitive processes, as discussed in this review. Thus, the gut microbiome may contribute to alterations in cognition in patients with CKD and may be a target for therapeutic interventions using diet, prebiotics and probiotics.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
